# Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications

Source: https://onco.cc/trials/nct05827614/  
OnCo record `nct05827614` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of BBI-355 run by Boundless Bio, Inc., terminated.

## Summary

Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications is a phase 1 interventional study registered as NCT05827614 by Boundless Bio, Inc., with 85 participants enrolled, started 2023-03-24. Conditions recorded: Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma, High Grade Endometrial Carcinoma, Anogenital Cancer, Head and Neck (HNSCC), Cutaneous Squamous Cell Carcinoma (CSCC), Cervical Squamous Cell Carcinoma, ER+ Breast Cancer, Leiomyosarcoma (LMS), Undifferentiated Pleomorphic Sarcoma (UPS), Pancreatic Cancer Metastatic and Small Cell Lung Cancer. Interventions recorded: BBI-355, Erlotinib, Futibatinib and BBI-825.

## Fields

- Kind: Trial
- Status: historic
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05827614
- Phase: 1
- Setting: An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Dose-Expansion, Phase 1/2 Study of BBI-355 and BBI-355 in Combination With Select Targeted Therapies in Subjects With Locally Advanced or Metastatic Solid Tumors With Oncogene Amplifications
- Sponsor: Boundless Bio, Inc.
- Enrolled: 85

## Sources

- ClinicalTrials.gov NCT05827614: https://clinicaltrials.gov/study/NCT05827614

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Cervical cancer](https://onco.cc/cancers/cervical/), [Cutaneous squamous cell carcinoma](https://onco.cc/cancers/cutaneous-scc/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/), [Undifferentiated pleomorphic sarcoma (UPS)](https://onco.cc/cancers/undifferentiated-pleomorphic-sarcoma/)
- drugs: [BBI-355](https://onco.cc/drugs/bbi-355/), [BBI-825](https://onco.cc/drugs/bbi-825/)
- companies: [Boundless Bio](https://onco.cc/companies/boundless-bio/)

---
JSON: https://onco.cc/api/v1/entities/nct05827614.json